Boron neutron capture therapy for newly diagnosed glioblastoma multiforme: an assessment of clinical potential
- 1 July 2010
- journal article
- research article
- Published by Oxford University Press (OUP) in The British Journal of Radiology
- Vol. 83 (991), 596-603
- https://doi.org/10.1259/bjr/56953620
Abstract
The purpose of this study was to assess the potential of boron neutron capture therapy (BNCT), with a 6-h infusion of the boron carrier l-boronophenylalanine as a fructose preparation (BPA-f), as first-line radiotherapy for newly diagnosed glioblastoma multiforme (GBM). Patient survival data from a Phase II study using BNCT were compared with retrospective data from the two arms of a Phase III study using conventional radiotherapy (RT) in the reference arm and using RT plus concomitant and adjuvant medication with temozolomide (TMZ) in the experimental arm, and were also compared with small subgroups of these patients for whom the methylation status of the MGMT (O(6)-methylguanine-DNA methyltransferase) DNA repair gene was known. Differences in the baseline characteristics, salvage therapy after recurrence and levels of severe adverse events were also considered. The results indicate that BNCT offers a treatment that is at least as effective as conventional RT alone. For patients with an unmethylated MGMT DNA repair gene, a possible clinical advantage of BNCT over RT/TMZ was suggested. BNCT is a single-day treatment, which is of convenience to patients, with mild side effects, which would offer an initial 6 weeks of good-quality life during the time when patients would otherwise be undergoing daily treatments with RT and TMZ. It is suggested that the use of BNCT with a 6-h infusion of BPA-f should be explored in a stratified randomised Phase II trial in which patients with the unmethylated MGMT DNA repair gene are offered BNCT in the experimental arm and RT plus TMZ in the reference arm.This publication has 18 references indexed in Scilit:
- Boron Neutron Capture Therapy for glioblastoma multiforme: advantage of prolonged infusion of BPA-fActa Neurologica Scandinavica, 2009
- Cost analysis of radiotherapy, carbon ion therapy, proton therapy and BNCT in JapanApplied Radiation and Isotopes, 2009
- An investigation of boron neutron capture therapy for recurrent glioblastoma multiformeActa Neurologica Scandinavica, 2008
- Neuropathological postmortem evaluation of BNCT for GBMActa Neurologica Scandinavica, 2007
- Radiotherapy and Temozolomide for Newly Diagnosed Glioblastoma: Recursive Partitioning Analysis of the EORTC 26981/22981-NCIC CE3 Phase III Randomized TrialJournal of Clinical Oncology, 2006
- Boron Neutron Capture Therapy of Cancer: Current Status and Future ProspectsClinical Cancer Research, 2005
- MGMTGene Silencing and Benefit from Temozolomide in GlioblastomaThe New England Journal of Medicine, 2005
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaThe New England Journal of Medicine, 2005
- Recursive Partitioning Analysis of Prognostic Factors in Three Radiation Therapy Oncology Group Malignant Glioma TrialsJNCI Journal of the National Cancer Institute, 1993